ABSTRACT
Objectives: The relationship between cathepsins and prostate cancer (PCa) has been reported. However, there is a lack of research on cathepsins and benign prostate diseases (BPDs). This study investigated the potential genetic link between cathepsins and BPDs through the utilization of Mendelian randomization (MR) analysis to determine if a causal relationship exists. Methods: Publicly accessible summary statistics on BPDs were obtained from FinnGen Biobank. The data comprised 149,363 individuals, with 30,066 cases and 119,297 controls for BPH, and 123,057 individuals, with 3,760 cases and 119,297 controls for prostatitis. The IEU OpenGWAS provided the Genome-wide association data on ten cathepsins. To evaluate the causal relationship between BPDs and cathepsins, five distinct MR analyses were employed, with the primary method being the inverse variance weighted (IVW) approach. Additionally, sensitivity analyses were conducted to examine the horizontal pleiotropy and heterogeneity of the findings. Results: The examination of IVW MR findings showed that cathepsin O had a beneficial effect on BPH (IVW OR=0.94, 95% CI 0.89-0.98, P=0.0055), while cathepsin X posed a threat to prostatitis (IVW OR=1.08, 95% CI 1.00-1.16, P=0.047). Through reverse MR analysis, it was revealed that prostatitis had an adverse impact on cathepsin V (IVW OR=0.89, 95% CI 0.80-0.99, P=0.035), while no favorable association was observed between BPH and cathepsins. The results obtained from MR-Egger, weighted median, simple mode, and weighted mode methods were consistent with the findings of the IVW approach. Based on sensitivity analyses, heterogeneity, and horizontal pleiotropy are unlikely to distort the results. Conclusion: This study offers the initial evidence of a genetic causal link between cathepsins and BPDs. Our findings revealed that cathepsin O was beneficial in preventing BPH, whereas cathepsin X posed a potential threat to prostatitis. Additionally, prostatitis negatively affected cathepsin V level. These three cathepsins could be targets of diagnosis and treatment for BPDs, which need further research.
Subject(s)
Cathepsins , Genome-Wide Association Study , Mendelian Randomization Analysis , Prostatic Hyperplasia , Humans , Male , Cathepsins/genetics , Prostatic Hyperplasia/genetics , Prostatic Hyperplasia/epidemiology , Polymorphism, Single Nucleotide , Case-Control Studies , Genetic Predisposition to Disease , Prostatic Neoplasms/genetics , Prostatic Neoplasms/epidemiology , Prostatitis/genetics , Prostatitis/epidemiology , Prostatic Diseases/genetics , Prostatic Diseases/epidemiologyABSTRACT
Despite extensive characterisation of uropathogenic Escherichia coli (UPEC) causing urinary tract infections (UTIs), the genetic background of non-urinary extraintestinal pathogenic E. coli (ExPEC) in companion animals remains inadequately understood. In this study, we characterised virulence traits of 104 E. coli isolated from canine pyometra (n = 61) and prostatic abscesses (PAs) (n = 38), and bloodstream infections (BSIs) in dogs (n = 2), and cats (n = 3). A stronger association with UPEC of pyometra strains in comparison to PA strains was revealed. Notably, 44 isolates exhibited resistance to third-generation cephalosporins and/or fluoroquinolones, 15 were extended-spectrum ß-lactamase-producers. Twelve multidrug-resistant (MDR) strains, isolated from pyometra (n = 4), PAs (n = 5), and BSIs (n = 3), along with 7 previously characterised UPEC strains from dogs and cats, were sequenced. Genomic characteristics revealed that MDR E. coli associated with UTIs, pyometra, and BSIs belonged to international high-risk E. coli clones, including sequence type (ST) 38, ST131, ST617, ST648, and ST1193. However, PA strains belonged to distinct lineages, including ST12, ST44, ST457, ST744, and ST13037. The coreSNPs, cgMLST, and pan-genome illustrated intra-clonal variations within the same ST from different sources. The high-risk ST131 and ST1193 (phylogroup B2) contained high numbers of ExPEC virulence genes on pathogenicity islands, predominating in pyometra and UTI. Hybrid MDR/virulence IncF multi-replicon plasmids, containing aerobactin genes, were commonly found in non-B2 phylogroups from all sources. These findings offer genomic insights into non-urinary ExPEC, highlighting its potential for invasive infections in pets beyond UTIs, particularly with regards to high-risk global clones.
Subject(s)
Abscess , Dog Diseases , Drug Resistance, Multiple, Bacterial , Escherichia coli Infections , Pyometra , Urinary Tract Infections , Dogs , Animals , Urinary Tract Infections/microbiology , Urinary Tract Infections/veterinary , Drug Resistance, Multiple, Bacterial/genetics , Male , Dog Diseases/microbiology , Cats , Escherichia coli Infections/microbiology , Escherichia coli Infections/veterinary , Pyometra/microbiology , Pyometra/veterinary , Pyometra/genetics , Abscess/microbiology , Abscess/veterinary , Female , Cat Diseases/microbiology , Uropathogenic Escherichia coli/genetics , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/pathogenicity , Escherichia coli/genetics , Escherichia coli/pathogenicity , Escherichia coli/drug effects , Anti-Bacterial Agents/pharmacology , Prostatic Diseases/microbiology , Prostatic Diseases/veterinary , Prostatic Diseases/genetics , Virulence/genetics , Virulence Factors/geneticsABSTRACT
The incidence of chronic aging-associated diseases, especially cardiovascular and prostatic diseases, is increasing with the aging of society. Evidence indicates that cardiovascular diseases usually coexist with prostatic diseases or increase its risk, while the pathological mechanisms of these diseases are unknown. Oxidative stress plays an important role in the development of both cardiovascular and prostatic diseases. The levels of oxidative stress biomarkers are higher in patients with cardiovascular diseases, and these also contribute to the development of prostatic diseases, suggesting cardiovascular diseases may increase the risk of prostatic diseases via oxidative stress. This review summarizes the role of oxidative stress in cardiovascular and prostatic diseases and also focuses on the main shared pathways underlying these diseases, in order to provide potential prevention and treatment targets.
Subject(s)
Cardiovascular Diseases/genetics , Oxidative Stress/genetics , Prostatic Diseases/genetics , Aging , Humans , MaleABSTRACT
Prostate cancer (PCa) is the most common cancer and the third most frequent cause of male cancer death in Germany. MicroRNAs (miRNA) appear to be involved in the development and progression of PCa. A diagnostic differentiation from benign prostate hyperplasia (BPH) is often only possible through transrectal punch biopsy. This procedure is described as painful and carries risks. It was investigated whether urinary miRNAs can be used as biomarkers to differentiate the prostate diseases above. Therefore urine samples from urological patients with BPH (25) or PCa (28) were analysed using Next-Generation Sequencing to detect the expression profile of total and exosomal miRNA/piRNA. 79 miRNAs and 5 piwi-interacting RNAs (piRNAs) were significantly differentially expressed (adjusted p-value < 0.05 and log2-Fc > 1 or < -1). Of these, 6 miRNAs and 2 piRNAs could be statistically validated (AUC on test cohort > = 0.7). In addition, machine-learning algorithms were used to identify a panel of 22 additional miRNAs, whose interaction makes it possible to differentiate the groups as well. There are promising individual candidates for potential use as biomarkers in prostate cancer. The innovative approach of applying machine learning methods to this kind of data could lead to further small RNAs coming into scientific focus, which have so far been neglected.
Subject(s)
MicroRNAs/metabolism , Prostate/metabolism , Prostatic Diseases/diagnosis , Prostatic Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biopsy , Diagnosis, Differential , High-Throughput Nucleotide Sequencing , Humans , Male , MicroRNAs/genetics , Middle Aged , Prostate/pathology , Prostatic Diseases/genetics , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathologyABSTRACT
Background/aim: This study aimed to examine serum paraoxonase 1 and 3 (PON1 and PON3) activities in benign and malignant diseases of the prostate, to determine lipid profile and malondialdehyde (MDA) levels, and to investigate changes in levels following robotic-assisted laparoscopic radical prostatectomy (RALRP). Materials and methods: A total of 137 patients, including a control group, were enrolled in the study and assigned into four groups. Group 1 (n = 33) consisted of patients previously undergoing RALRP with no recurrence, group 2 (n = 36) consisted of patients diagnosed with prostate cancer (PCa) and undergoing RALRP, and group 3 (n = 34) consisted of patients diagnosed with benign prostatic hyperplasia. The control group (n = 34) consisted of healthy individuals. Serum low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, cholesterol, prostate-specific antigen (PSA), PON1, PON3, and MDA values were measured. In addition, group 2 MDA, PON1, PON3, and PON1/HDL levels were investigated preoperatively and at the first month postoperatively. Results: Significant changes were found in PON1, PON3, and MDA levels. PON1 and PON3 levels decreased significantly in patients with PCa, while MDA levels increased. PON1 and PON3 increased postoperatively in the PCa group, while MDA decreased. BPH group PON1, PON3, and MDA levels were higher than those of the control group. Conclusion: An increase in free oxygen radicals in the body or a decrease in endogenous antioxidant enzyme levels can result in malignant and benign diseases of the prostate. Surgical excision of malignant tissue in PCa causes a decrease in oxidative stress.
Subject(s)
Aryldialkylphosphatase/blood , Laparoscopy/methods , Prostatectomy/methods , Prostatic Diseases/blood , Prostatic Diseases/surgery , Robotic Surgical Procedures/methods , Aged , Aryldialkylphosphatase/genetics , Humans , Male , Malondialdehyde/blood , Middle Aged , Prostate/surgery , Prostatic Diseases/geneticsABSTRACT
OBJECTIVE: In the literature, the BRAF mutation is reported to have been identified in 80 % of the examined canine prostate carcinomas (PCa). The objectives of this study were to test for the BRAF mutation in canine PCa in our cohort of canine patients, to determine the specificity and sensitivity of the test for this mutation, as well as to identify the association between the presence of the BRAF mutation and the histologic picture of PCa. Moreover, the method was to be established in cytology samples. MATERIAL AND METHODS: Biopsy samples (n = 70) and cytologic slides (n = 17) of 87 dogs with prostatic diseases were selected. Prostatic diseases were classified according to the literature as benign prostate hyperplasia (BPH, n = 22), prostatitis (n = 14), squamous cell metaplasia of the prostate (PM, n = 2), atrophy following castration (n = 3) und PCa (n = 46; histologic diagnosis n = 35, cytologic diagnosis n = 11). Additionally, the Gleason score was determined for each PCa. DNA isolation was performed using commercially available kits. Exon 15 was examined using the TaqMan® SNP assay. The specificity and sensitivity of the test were calculated. RESULTS: A Gleason score of 6 and 7 was shown in 1 PCa each, in 33 cases the score ranged between 8 and 10. Sufficient amount of good-quality DNA was isolated from all samples. 28/46 PCa were tested positive for the BRAF mutation (sensitivity 61 %). The BRAF mutation was not evident in any of the dogs with BPH, prostatitis, PM or atrophy (specificity 100 %). PCa positive for the BRAF mutation exhibited a significantly higher Gleason score (p = 0.002) in comparison to PCa without this mutation. CONCLUSION AND CLINICAL RELEVANCE: BRAF mutation analysis is a highly specific method and may aid in confirming the diagnosis of PCa in histologically and cytologically questionable cases. PCa positive for BRAF mutation exhibited more criteria of malignancy than PCa without this mutation. The clinical, therapeutic, and prognostic relevance of these findings needs to be evaluated by further studies.
Subject(s)
Dog Diseases/genetics , Mutation , Prostatic Diseases/veterinary , Proto-Oncogene Proteins B-raf/genetics , Animals , Dog Diseases/diagnosis , Dog Diseases/enzymology , Dog Diseases/pathology , Dogs , Genetic Markers/genetics , Male , Prostatic Diseases/diagnosis , Prostatic Diseases/genetics , Prostatic Diseases/pathologyABSTRACT
Exposure to vinclozolin has been shown to induce the epigenetic transgenerational inheritance of increased susceptibility to disease, and to induce transgenerational changes to the epigenome. In the current study, gestating F0 generation rats were exposed to vinclozolin, and the subsequent F1, F2 and transgenerational F3 generations were evaluated for diseases and pathologies. F1 and F2 generation rats exhibited few abnormalities. However, F3 generation rats showed transgenerational increases in testis, prostate, and kidney disease, changes in the age of puberty onset in males, and an increased obesity rate in females. Overall there was an increase in the rate of animals with disease, and in the incidence of animals with multiple diseases. The objective of the current study was to analyze the sperm epigenome of F3 generation rats with specific abnormalities and compare them to rats without those abnormalities, in an effort to find epigenetic biomarkers of transgenerational disease. Unique signatures of differential DNA methylation regions (DMRs) in sperm were found that associated with testis disease, prostate disease and kidney disease. Confounding factors identified were the presence of multiple diseases in the analysis and the limited number of animals without disease. These results further our understanding of the mechanisms governing epigenetic transgenerational inheritance, and may lead in the future to the use of epigenetic biomarkers that will help predict an individual's susceptibility for specific diseases.
Subject(s)
Biomarkers/metabolism , Epigenesis, Genetic/drug effects , Fungicides, Industrial/toxicity , Oxazoles/toxicity , Spermatozoa/drug effects , Animals , Behavior, Animal/drug effects , Chromosome Mapping , Chromosomes/genetics , Chromosomes/metabolism , DNA Methylation , Female , Heredity/genetics , Kidney Diseases/etiology , Kidney Diseases/genetics , Kidney Diseases/pathology , Male , Pregnancy , Prenatal Exposure Delayed Effects , Prostatic Diseases/etiology , Prostatic Diseases/genetics , Prostatic Diseases/pathology , Rats , Rats, Sprague-Dawley , Spermatozoa/metabolism , Testis/pathologyABSTRACT
Existing drugs that have been used in clinical practice for other purposes can prove useful for reutilization, since much of the safety profile and pharmacokinetics have been completed. Therefore, the drugs can enter clinical practice for a variety of causes with less regulatory burden. Metformin may prove to be such a drug; it may have a role in other diseases, besides the management of diabetes. In this perspective, we provide our findings and understanding of metformin as an alternative way to treat urological abnormal proliferation. We propose the potential mechanisms into two hallmarks: direct antiproliferative function via insulin-like growth factor (IGF) signaling pathway and epigenetic modulating via adjusting DNA methylation. These specific hallmarks may ultimately contribute to a better understanding of metformin in treating prostatic diseases.
Subject(s)
Cell Proliferation/drug effects , DNA Methylation/drug effects , Epigenesis, Genetic/drug effects , Metformin/pharmacology , Prostate/drug effects , Prostatic Diseases/drug therapy , Urological Agents/pharmacology , Animals , Humans , Male , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/genetics , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Signal Transduction/drug effectsABSTRACT
Besides androgens, estrogen signaling plays a key role in normal development and pathologies of the prostate. Irreversible synthesis of estrogens from androgens is catalyzed by aromatase. Interestingly, animals lacking aromatase do not develop cancer or prostatitis, whereas those with overexpression of aromatase and, consequently, high estrogen levels develop prostatitis and squamous metaplasia via estrogen receptor 1 (ERα). Even with this evidence, the aromatase expression in the prostate is controversial. Moreover, little is known about the occurrence of age-dependent variation of aromatase and its association with histopathological changes commonly found in advanced age, a knowledge gap that is addressed herein. For this purpose, the immunoexpression of aromatase was evaluated in the prostatic complex of young adult to senile Wistar rats. ERα was also investigated, to extend our understanding of estrogen responsiveness in the prostate. Moderate cytoplasmic immunoreactivity for aromatase was detected in the glandular epithelium. Eventually, some basal cells showed intense staining for aromatase. The expression pattern for aromatase appeared similar in the normal epithelium when young and senile rats were compared; this result was corroborated by Western blotting. Conversely, in senile rats, there was an increase in the frequency of basal cells intensely stained for aromatase, which appeared concentrated in areas of intraepithelial proliferation and prostatitis. These punctual areas also presented increased ERα positivity. Together, these findings suggest a plausible source for hormonal imbalance favoring estrogen production, which, by acting through ERα, may favor the development of prostatic lesions commonly found in advanced age.
Subject(s)
Aromatase/metabolism , Epithelium/metabolism , Estrogen Receptor alpha/metabolism , Prostate/metabolism , Prostatic Diseases/metabolism , Androgens/metabolism , Animals , Aromatase/genetics , Epithelium/enzymology , Estrogen Receptor alpha/genetics , Estrogens/metabolism , Humans , Male , Prostate/enzymology , Prostatic Diseases/enzymology , Prostatic Diseases/genetics , Rats , Rats, WistarABSTRACT
Silent information regulator 1(SIRT1),an NAD+dependent class-III histone deacetylase,is implicated in diverse cellular processes. SIRT1 has been reported as a key regulator of metabolism,oxidative stress,and cell survival,proliferation,apoptosis and autophagy. It also plays an important role in a variety of physiological processes and health conditions,including aging,inflammation,metabolic disease,tumor,cardiovascular disease,and neurodegeneration. In recent years,the incidence of prostate diseases is increasing,but the therapeutic options are relatively limited. The importance of SIRT1 in prostate diseases has become increasingly apparent,and more rational application of sirtuin inhibitors or activators is shedding new light on the management of prostate diseases.This review focuses on the role of SIRT1 in prostate diseases and introduces some novel strategies for their diagnosis and treatment.
Subject(s)
Prostatic Diseases/genetics , Sirtuin 1/genetics , Animals , Apoptosis , Autophagy , Cell Survival , Humans , Male , Oxidative StressABSTRACT
PURPOSE: To compare dietary, lifestyle, clinical, anthropometric, genetic and prostatic features of Brazilian Indians and non-Indians (Amazon). METHODS: 315 men, 228 Indians and 89 non-Indians, ≥ 40 years old were submitted to digital rectal examination, serum prostate specific antigen (PSA), testosterone, TP53 and GSTP1 genotyping, anthropometric, lifestyle, dietary, personal and familial medical history. Prostatic symptoms were evaluated with the International Prostate Symptom Score (IPSS). RESULTS: Macuxis and Yanomamis represented 43.6% and 14.5% of Indians respectively who spontaneously referred no prostate symptoms. Mean IPSS was 7, range 3-19, with only 15% of moderate symptoms (score 8-19); Mean age was 54.7 years, waist circumference 86.6 cm, BMI 23.9 kg/m(2). Yanomamis presented both lower BMI (21.4 versus 24.8 and 23.3, p=0,001) and prostate volume than Macuxis and "other ethnic groups" (15 versus 20, p=0.001). Testosterone (414 versus 502 and 512, p=0.207) and PSA (0.48 versus 0.6 and 0.41, p=0.349) were similar with progressive PSA increase with aging. Val/Val correlated with lower PSA (p=0.0361). Indians compared to control population presented: - TP53 super representation of Arg/Arg haplotype, 74.5% versus 42.5%, p<0.0001. -GSTP1 Ile/Ile 35.3% versus 60.9%; Ile/Val 45.9% versus 28.7%; Val/Val 18.8% versus 10.3%; p=0.0003. CONCLUSIONS: Observed specific dietary, lifestyle, anthropometric and genetic profile for TP53 and GSTP1 may contribute to Brazilian Indian population prostate good health.
Subject(s)
Anthropometry , Indians, South American/statistics & numerical data , Prostate/anatomy & histology , Prostatic Diseases/ethnology , Prostatic Diseases/genetics , Adult , Age Factors , Aged , Aged, 80 and over , Brazil , Digital Rectal Examination , Feeding Behavior/ethnology , Glutathione S-Transferase pi/genetics , Humans , Life Style/ethnology , Male , Middle Aged , Organ Size , Polymorphism, Genetic , Prostate-Specific Antigen/blood , Risk Factors , Statistics, Nonparametric , Tumor Suppressor Protein p53/geneticsABSTRACT
Purpose To compare dietary, lifestyle, clinical, anthropometric, genetic and prostatic features of Brazilian Indians and non-Indians (Amazon). Methods 315 men, 228 Indians and 89 non-Indians, ≥40 years old were submitted to digital rectal examination, serum prostate specific antigen (PSA), testosterone, TP53 and GSTP1 genotyping, anthropometric, lifestyle, dietary, personal and familial medical history. Prostatic symptoms were evaluated with the International Prostate Symptom Score (IPSS). Results Macuxis and Yanomamis represented 43.6% and 14.5% of Indians respectively who spontaneously referred no prostate symptoms. Mean IPSS was 7, range 3-19, with only 15% of moderate symptoms (score 8-19); Mean age was 54.7 years, waist circumference 86.6 cm, BMI 23.9 kg/m2. Yanomamis presented both lower BMI (21.4 versus 24.8 and 23.3, p=0,001) and prostate volume than Macuxis and “other ethnic groups” (15 versus 20, p=0.001). Testosterone (414 versus 502 and 512, p=0.207) and PSA (0.48 versus 0.6 and 0.41, p=0.349) were similar with progressive PSA increase with aging. Val/Val correlated with lower PSA (p=0.0361). Indians compared to control population presented: - TP53 super representation of Arg/Arg haplotype, 74.5% versus 42.5%, p<0.0001. -GSTP1 Ile/Ile 35.3% versus 60.9%; Ile/Val 45.9% versus 28.7%; Val/Val 18.8% versus 10.3%; p=0.0003. Conclusions Observed specific dietary, lifestyle, anthropometric and genetic profile for TP53 and GSTP1 may contribute to Brazilian Indian population prostate good health. .
Subject(s)
Adult , Aged , Aged, 80 and over , Humans , Male , Middle Aged , Anthropometry , Indians, South American/statistics & numerical data , Prostate/anatomy & histology , Prostatic Diseases/ethnology , Prostatic Diseases/genetics , Age Factors , Brazil , Digital Rectal Examination , Feeding Behavior/ethnology , Glutathione S-Transferase pi/genetics , Life Style/ethnology , Organ Size , Polymorphism, Genetic , Prostate-Specific Antigen/blood , Risk Factors , Statistics, Nonparametric , /geneticsABSTRACT
BACKGROUND: To use spectra acquired by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) from pre- and post-digital rectal examination (DRE) urine samples to search for discriminating peaks that can adequately distinguish between benign and malignant prostate conditions, and identify the peaks' underlying biomolecules. METHODS: Twenty-five participants with prostate cancer (PCa) and 27 participants with a variety of benign prostatic conditions as confirmed by a 10-core tissue biopsy were included. Pre- and post-DRE urine samples were prepared for MALDI MS profiling using an automated clean-up procedure. Following mass spectra collection and processing, peak mass and intensity were extracted and subjected to statistical analysis to identify peaks capable of distinguishing between benign and cancer. Logistic regression was used to combine markers to create a sensitive and specific test. RESULTS: A peak at m/z 10,760 was identified as ß-microseminoprotein (ß-MSMB) and found to be statistically lower in urine from PCa participants using the peak's average areas. By combining serum prostate-specific antigen (PSA) levels with MALDI MS-measured ß-MSMB levels, optimum threshold values obtained from Receiver Operator characteristics curves gave an increased sensitivity of 96% at a specificity of 26%. CONCLUSIONS: These results demonstrate that with a simple sample clean-up followed by MALDI MS profiling, significant differences of MSMB abundance were found in post-DRE urine samples. In combination with PSA serum levels, obtained from a classic clinical assay led to high classification accuracy for PCa in the studied sample set. Our results need to be validated in a larger multicenter prospective randomized clinical trial.
Subject(s)
Biomarkers, Tumor/urine , Digital Rectal Examination , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/urine , Prostatic Secretory Proteins/urine , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Gene Expression Profiling/methods , Gene Regulatory Networks/genetics , Humans , Male , Middle Aged , Prostatic Diseases/diagnosis , Prostatic Diseases/genetics , Prostatic Diseases/urine , Prostatic Neoplasms/genetics , Prostatic Secretory Proteins/geneticsABSTRACT
BACKGROUND/AIM: In human prostate cancer cells with a stem cell-like character (cancer stem cells, CSC) are considered to play a major role in disease development, progression and relapse. Aim of the study was to evaluate if similar cells are present and active in canine prostate cancer providing a naturally-occurring mammalian model for the development of therapeutic approaches targeting CSC. MATERIALS AND METHODS: Stem cell marker expression of CD133, CD44, C-KIT, CD34, ITGA6, OCT4, DDX5 and MELK in canine prostate carcinomas and prostate cyst cell lines were screened by Polymerase Chain Reaction (PCR), quantitative Polymerase Chain Reaction (qPCR) and partially analysed by flow cytometry. RESULTS: Marker analyses by PCR and qPCR, revealed a complex expression pattern for the analysed marker genes, providing a characteristic marker pattern for the studied cell lines. Thereby CD44, CD133, ITGA6 and DDX5 showed the most prominent expression in the analysed cell lines. CONCLUSION: The results revealed a characteristic stem cell marker expression in the analysed cell lines, indicating the presence of CSC in canine prostate cancer.
Subject(s)
Biomarkers/metabolism , Gene Expression , Prostatic Diseases/veterinary , Prostatic Neoplasms/veterinary , Stem Cells/metabolism , Animals , Base Sequence , Cell Line , Cysts/genetics , Cysts/pathology , Cysts/veterinary , DNA Primers , Dogs , Male , Prostatic Diseases/genetics , Prostatic Diseases/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Real-Time Polymerase Chain ReactionABSTRACT
Androgen-driven stromal-epithelial interactions play a key role in normal prostate development and function as well as in the progression of common prostatic diseases such as benign prostatic hyperplasia and prostate cancer. However, exactly how, and via which cell type, androgens mediate their effects in the adult prostate remains unclear. This study investigated the role for smooth muscle (SM) androgen signaling in normal adult prostate homeostasis and function using mice in which androgen receptor was selectively ablated from prostatic SM cells. In adulthood the knockout (KO) mice displayed a 44% reduction in prostate weight and exhibited histological abnormalities such as hyperplasia, inflammation, fibrosis, and reduced expression of epithelial, SM, and stem cell identify markers (e.g. p63 reduced by 27% and Pten by 31%). These changes emerged beyond puberty and were not explained by changes in serum hormones. Furthermore, in response to exogenous estradiol, adult KO mice displayed an 8.5-fold greater increase in prostate weight than controls and developed urinary retention. KO mice also demonstrated a reduced response to castration compared with controls. Together these results demonstrate that prostate SM cells are vital in mediating androgen-driven stromal-epithelial interactions in adult mouse prostates, determining cell identity and function and limiting hormone-dependent epithelial cell proliferation. This novel mouse model provides new insight into the possible role for SM androgen action in prostate disease.
Subject(s)
Disease Models, Animal , Myocytes, Smooth Muscle/metabolism , Prostatic Diseases/genetics , Receptors, Androgen/genetics , Animals , Male , Mice , Mice, Knockout , Mitosis/physiology , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/metabolism , Prostatic Diseases/pathology , Receptors, Androgen/metabolismSubject(s)
Carcinoma/therapy , Prostatic Diseases/therapy , Prostatic Neoplasms/therapy , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Carcinoma/etiology , Carcinoma/genetics , Carcinoma/prevention & control , Diet Therapy/methods , Dietary Supplements , Humans , Male , Prostatic Diseases/etiology , Prostatic Diseases/genetics , Prostatic Neoplasms/etiology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/prevention & controlABSTRACT
PURPOSE: The ability of an endocrine disruptor exposure during gonadal sex determination to promote a transgenerational prostate disease phenotype was investigated in the current study. METHODS: Exposure of an F0 gestating female rat to the endocrine disruptor vinclozolin during F1 embryo gonadal sex determination promoted a transgenerational adult onset prostate disease phenotype. The prostate disease phenotype and physiological parameters were determined for males from F1 to F4 generations and the prostate transcriptome was assessed in the F3 generation. RESULTS: Although the prostate in prepubertal animals develops normally, abnormalities involving epithelial cell atrophy, glandular dysgenesis, prostatitis, and hyperplasia of the ventral prostate develop in older animals. The ventral prostate phenotype was transmitted for four generations (F1-F4). Analysis of the ventral prostate transcriptome demonstrated 954 genes had significantly altered expression between control and vinclozolin F3 generation animals. Analysis of isolated ventral prostate epithelial cells identified 259 genes with significantly altered expression between control and vinclozolin F3 generation animals. Characterization of regulated genes demonstrated several cellular pathways were influenced, including calcium and WNT. A number of genes identified have been shown to be associated with prostate disease and cancer, including beta-microseminoprotein (Msp) and tumor necrosis factor receptor superfamily 6 (Fadd). CONCLUSIONS: The ability of an endocrine disruptor to promote transgenerational prostate abnormalities appears to involve an epigenetic transgenerational alteration in the prostate transcriptome and male germ-line. Potential epigenetic transgenerational alteration of prostate gene expression by environmental compounds may be important to consider in the etiology of adult onset prostate disease.
Subject(s)
Androgen Antagonists/pharmacology , Gene Expression Profiling , Gene Expression Regulation, Developmental/drug effects , Oxazoles/pharmacology , Prenatal Exposure Delayed Effects/genetics , Prostate/drug effects , Prostatic Diseases/genetics , Animals , Calcium/metabolism , Epigenesis, Genetic/genetics , Female , Male , Phenotype , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Prostate/metabolism , Prostate/pathology , Prostatic Diseases/metabolism , Prostatic Secretory Proteins/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Tumor Necrosis Factor/metabolism , Sex Determination Processes , Wnt Proteins/metabolismABSTRACT
Human aldo-keto reductases (AKR) of the 1A, 1B, 1C and 1D subfamilies are involved in the pre-receptor regulation of nuclear (steroid hormone and orphan) receptors by regulating the local concentrations of their lipophilic ligands. AKR1C3 is one of the most interesting isoforms. It was cloned from human prostate and the recombinant protein was found to function as a 3-, 17- and 20-ketosteroid reductase with a preference for the conversion of Delta4-androstene-3,17-dione to testosterone implicating this enzyme in the local production of active androgens within the prostate. Using a validated isoform specific real-time RT-PCR procedure the AKR1C3 transcript was shown to be more abundant in primary cultures of epithelial cells than stromal cells, and its expression in stromal cells increased with benign and malignant disease. Using a validated isoform specific monoclonal Ab, AKR1C3 protein expression was also detected in prostate epithelial cells by immunoblot analysis. Immunohistochemical staining of prostate tissue showed that AKR1C3 was expressed in adenocarcinoma and surprisingly high expression was observed in the endothelial cells. These cells are a rich source of prostaglandin G/H synthase 2 (COX-2) and vasoactive prostaglandins (PG) and thus the ability of recombinant AKR1C enzymes to act as PGF synthases was compared. AKR1C3 had the highest catalytic efficiency (kcat/Km) for the 11-ketoreduction of PGD2 to yield 9alpha,11beta-PGF2 raising the prospect that AKR1C3 may govern ligand access to peroxisome proliferator activated receptor (PPARgamma). Activation of PPARgamma is often a pro-apoptotic signal and/or leads to terminal differentiation, while 9alpha,11beta-PGF2 is a pro-proliferative signal. AKR1C3 is potently inhibited by non-steroidal anti-inflammatory drugs suggesting that the cancer chemopreventive properties of these agents may be mediated either by inhibition of AKR1C3 or COX. To discriminate between these effects we developed potent AKR1C inhibitors based on N-phenylanthranilic acids that do not inhibit COX-1 or COX-2. These compounds can now be used to determine the role of AKR1C3 in producing two proliferative signals in the prostate namely testosterone and 9alpha,11beta-PGF2.
Subject(s)
3-Hydroxysteroid Dehydrogenases/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Drug Design , Enzyme Inhibitors/pharmacology , Hydroxyprostaglandin Dehydrogenases/antagonists & inhibitors , Prostatic Diseases/enzymology , 3-Hydroxysteroid Dehydrogenases/analysis , 3-Hydroxysteroid Dehydrogenases/physiology , Aldo-Keto Reductase Family 1 Member C3 , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Dinoprost/biosynthesis , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Gonadal Steroid Hormones/biosynthesis , Gonadal Steroid Hormones/metabolism , Humans , Hydroxyprostaglandin Dehydrogenases/analysis , Hydroxyprostaglandin Dehydrogenases/physiology , Male , Prostate/enzymology , Prostatic Diseases/genetics , Structure-Activity Relationship , Testosterone/biosynthesis , Transcription, GeneticABSTRACT
Atypical adenomatous hyperplasia (AAH) of the prostate is a microscopic proliferation of small acini that may be mistaken for adenocarcinoma. Although some data suggest that AAH is associated with adenocarcinoma arising in the transition zone, the clinical significance of this lesion is uncertain. Therefore we studied the DNA ploidy pattern and immunophenotype of AAH as compared with nodular hyperplasia and well-differentiated adenocarcinoma in 23 formalin-fixed, paraffin-embedded, whole-mounted retropubic prostatectomies. Representative sections were immunostained for keratin 34beta-E12, chromogranin, bcl-2, c-erbB-2, ki67-MIB1, and factor VIII (microvessel density). DNA ploidy was determined by image analysis and Feulgen-stained sections. There were rare scattered immunoreactive cells for chromogranin, bcl-2, and c-erbB-2 in nodular hyperplasia and AAH (mainly in the basal cell compartment) and in carcinoma. The ki67-MIB1 labeling index was different between nodular hyperplasia and AAH (p<0.001) and carcinoma (p=0.003) but not between AAH and carcinoma (p=0.203). Microvessel density was different between AAH and carcinoma (p=0.001) but not between nodular hyperplasia and AAH (p=0.105) or carcinoma (p=0.0820). All foci of nodular hyperplasia, AAH, and carcinoma were diploid. Ploidy status and our selected panel of antibodies did not discriminate among these 3 entities reliably.